Table 1.
Experimental evidence of a role for T helper type 1 (Th1) and Th17 cells in experimental autoimmune encephalomyelitis (EAE).
| Molecule/cell type* | Manipulation† | Background‡ | Induction method§ | Effect on EAE¶ | Reference |
|---|---|---|---|---|---|
| IL-12p40 | Genetic deletion | C57BL/6 | MOG/CFA | Resistant | [15] |
| IL-12p35 | Genetic deletion | C57BL/6 | MOG/CFA | Susceptible | [15] |
| IL-23p19 | Genetic deletion | B6×129 | MOG/CFA | Resistant | [15,38] |
| IL-23p19 | α-IL-23p19 pre-onset | SJL | PLP/CFA | Resistant | [114] |
| IL-23p19 | α-IL-23p19 post-onset | SJL | PLP/CFA | Prevented relapse | [114] |
| IL-23p19 | Genetic deletion (recipient only) | C57BL/6 | WT T cell transfer | Susceptible | [38] |
| IL-23p19 | Genetic deletion (donor only) | C57BL/6 | p19−/− T cell transfer | Delayed-onset reduced severity | [38] |
| IL-6 | Genetic deletion | 129Sv×C57BL/6 | MOG/CFA | Resistant | [115] |
| IL-6R | T cell conditional deletion of gp130 | C57BL/6 | MOG/CFA | Resistant | [116] |
| IL-1R | Genetic deletion | C57BL/6 | MOG/CFA | Resistant | [20] |
| IFN-γ | Genetic deletion | B10.PL | MBP/CFA | Increased mortality delayed resolution? | [13] |
| Tbet | Genetic deletion | C57BL/6 | MOG/CFA | Resistant | [14] |
| STAT1 | Genetic deletion | C57BL/6 | MOG/CFA | Increased severity | [14] |
| IL-17 | Genetic deletion | C57BL/6 | MOG/CFA | Delayed-onset reduced severity | [26,27]** |
| IL-25 | Genetic deletion | C57BL/6 | MOG/CFA | Accelerated-onset enhanced severity | [117] |
| IL-21/IL-21R | Genetic deletion | C57BL/6 | MOG/CFA | Susceptible | [28] |
| IL-22 | Genetic deletion | C57BL/6 | MOG/CFA | Susceptible | [29] |
| IL-9/IL-9R | Neutralization/genetic deletion | C57BL/6 | MOG/CFA | Delayed-onset/attenuated disease | [30] |
| Th1 | Adoptive transfer | C57BL/6 | Th1 transfer | Induced disease | [7] |
| Th1 | Adoptive transfer | SJL | Th1 transfer | Failed to induce disease | [16] |
| Th1 | Adoptive transfer | SJL | Th1 transfer | Induced disease | [32] |
| Th17 | Adoptive transfer | C57BL/6 | Th17 transfer | Failed to induce disease | [7] |
| Th17 | Adoptive transfer | SJL | Th17 transfer | Induced disease | [16,32] |
Molecule or cell type of interest that was manipulated in each study.
Approaches taken to manipulate cells or molecules include gene deletion, administration of neutralizing antibody or adoptive transfer of T cell lines.
Mouse strain background.
Methods used to induce EAE include active induction with myelin-antigens plus complete Freund's adjuvant (CFA) or passive induction by adoptive transfer of T cell lines.
Effect of manipulation on the clinical symptoms of EAE.
Found only marginal contribution after deletion of interleukin (IL)-17A and IL-17F. IFN: interferon; MOG: myelin–oligodendrocyte–glycoprotein; PLP: proteolipid protein; STAT1: signal transducer and activation of transcription-1; WT: wild-type.